Should I Buy RMTI? RMTI 2026 Analysis

Should You Buy Rockwell Medical Inc (RMTI) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Hold

Latest Price

1.090

1 Day change

-3.54%

52 Week Range

2.120

Analysis Updated At

2026/01/26

Rockwell Medical Inc (RMTI) is not a strong buy for a beginner, long-term investor at this time. The company's financial performance has been declining, with significant YoY drops in revenue, net income, and EPS. Despite slightly exceeding Q4 2025 sales expectations, the overall trend remains negative. Technical indicators do not show a clear bullish signal, and there are no strong trading signals from Intellectia Proprietary Trading Signals. Additionally, analysts have reduced the price target, and there are no significant positive catalysts to justify immediate investment.

Technical Analysis

The MACD is positive but contracting, RSI is neutral at 62.859, and moving averages are converging. Key support and resistance levels are Pivot: 1.087, R1: 1.228, and S1: 0.946. The stock has a 70% chance to drop -3.32% in the next week and -0.16% in the next month, indicating limited upside potential in the short term.

Options Data

Bullish

Open Interest Put-Call Ratio

Bullish

Option Volume Put-Call Ratio

Technical Summary

Sell

Buy

Positive Catalysts

Q4 2025 net sales of $18.6 million exceeded analysts' expectations of $16.55 million.

Neutral/Negative Catalysts

Revenue, net income, EPS, and gross margin have all significantly declined YoY. Analysts have reduced the price target from $3 to $2.50, citing a 'slight' top-line miss and limited benefit from large contracts.

Financial Performance

In Q3 2025, revenue dropped by -43.75% YoY to $15.93 million, net income dropped by -222.50% YoY to -$1.75 million, EPS dropped by -225.00% YoY to -0.05, and gross margin fell by -21.02% YoY to 17.4%.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

H.C. Wainwright has lowered the price target to $2.50 from $3 while maintaining a Buy rating. The firm notes a 'slight' top-line miss and limited potential from large contracts, despite a more diversified revenue base.

2 Analyst Rating

Wall Street analysts forecast RMTI stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for RMTI is 3.75 USD with a low forecast of 2.5 USD and a high forecast of 5 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

2 Buy

0 Hold

0 Sell

Moderate Buy

Current: 1.130

Low

2.5

Averages

3.75

High

Current: 1.130

Low

2.5

Averages

3.75

High

H.C. Wainwright

Buy

downgrade

AI Analysis

2025-11-13

Reason

H.C. Wainwright

Price Target

AI Analysis

2025-11-13

downgrade

Buy

Reason

H.C. Wainwright lowered the firm's price target on Rockwell Medical to $2.50 from $3 and keeps a Buy rating on the shares after the company reported a "slight" top-line miss in Q3. The firm, which has adjusted its long-term forecasts, tells investors that the company's revenue base, while "meaningfully more diversified" than in the past, may not benefit from large contracts as much as in the past.

HC Wainwright & Co.

Raghuram Selvaraju

Strong Buy

Maintains

$7 → $3

2025-03-24

Reason

HC Wainwright & Co.

Raghuram Selvaraju

Price Target

$7 → $3

2025-03-24

Maintains

Strong Buy

Reason

RMTI Should I Buy

RMTI Should I Buy

Should You Buy Rockwell Medical Inc (RMTI) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Technical Summary

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch